| Intellect application supported by written declaration from independent, world renowned academic expert in therapeutic antibodies NEW YORK, Nov. 3, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it has filed a response and request for continued examination (RCE) in its antibody methods appli...continued ILNS memory intellect Healthcare |
Thursday, November 3, 2011
Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN( Alzheimer's Patent Application
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment